吴琳琳,刘捷宸,邵慧勇,孙晓冬

• 1:上海市疾病预防控制中心

摘要(Abstract)：

目的了解上海市肠道病毒71型(EV71)灭活疫苗接种率和疑似预防接种异常反应(AEFI)发生率。方法通过上海市免疫规划信息系统、中国AEFI监测信息管理系统收集2013年10月-2019年3月出生儿童EV71疫苗接种和AEFI数据,分析EV71疫苗接种率和AEFI发生率。结果上海市2013年10月-2019年3月出生儿童EV71疫苗1剂次接种率为38.30%,2剂次(全程)接种率为35.05%。本市、外来人口1剂次接种率分别为46.34%、33.89%,2剂次接种率分别为43.61%、30.36%;各年龄组1剂次接种率在20.49%-52.71%之间,2剂次接种率在17.34%-49.85%之间。EV71疫苗接种后AEFI报告发生率为224.91/10万剂(3 046例);其中一般反应、异常反应分别为217.08/10万剂(2 940例)、6.87/10万剂(93例),分别以发热(2 263例,167.09/10万剂)、过敏性皮疹(87例,6.42/10万剂)为主。结论上海市儿童EV71疫苗接种率不高,AEFI报告发生率在预期范围内;仍应加强EV71疫苗接种宣传,提高儿童接种率。

关键词(KeyWords)： 肠道病毒71型灭活疫苗;接种率;疑似预防接种异常反应;监测

Abstract:

Keywords:

基金项目(Foundation): 上海市卫生和计划生育委员会科研课题（20184Y0243）

作者(Author): 吴琳琳,刘捷宸,邵慧勇,孙晓冬

参考文献(References)：

• [1]中华人民共和国卫生部.手足口病诊疗指南[S]. 2010.Ministry of Health of the People’s Republic of China.Guidelines for diagnosis and treatment of hand, foot and mouth disease[S]. 2010.
• [2]安志杰,刘艳,廖巧红,等.肠道病毒71型灭活疫苗使用技术指南[J].中国疫苗和免疫, 2016, 22(4):458-464. AN Zhijie, LIU Yan, LIAO Qiaohong, et al. Technical guideline for the use of inactivated enterovirus type 71 vaccines[J]. Chinese Journal of Vaccines and Immunization, 2016,22(4):458-464.
• [3]杨芳,于石成,张菊英,等. 2008—2011年我国大陆地区重症手足口病流行特征分析[J].疾病监测, 2013, 28(11):888-893. YANG Fang, YU Shicheng, ZHANG Juying, et al.Epidemiology of severe hand foot and mouth disease in the mainland of China, 2008-2011[J]. Disease Surveillance[J]. 2013, 28(11):888-893.
• [4] MAO QY, WANG Y, BIAN L, et al. EV71 vaccine, a new toll control outbreaks of hand, foot and mouth disease(HFMD)[J]. Expert Review of Vaccines, 2016, 15(5):599-606.
• [5]卫生部办公厅,国家食品药品监督管理办公室.全国疑似预防接种异常反应监测方案[S]. 2010-06-03. General Office of Ministry of Health, General Off ice of State Food and Drug Administration. National guideline for surveillance of adverse events following immunization[S]. 2010-06-03.
• [6]龙遗芳,李胜峰,谢莘,等.广东省2017年肠道病毒71型灭活疫苗接种现况分析[J].华南预防医学, 2018, 44(4):349-351. LONG Yif ang, LI Shengfeng, XIE Shen, et al.Current status of inoculating inactivated enterovirus 71vaccine in Guangdong province, 2017[J]. South China Journal of Preventive Medicine, 2018, 44(4):349-351.
• [7]章光明,吴晓虹,金祝平,等.金华市EV71灭活疫苗接种水平分析[J].预防医学, 2019, 31(10):1022-1024.ZHANG Guangming, WU Xiaohong, JIN Zhuping, et al. Vaccination of enterovirus 71 inactivated vaccine in Jinhua[J]. Preventive Medicine, 2019, 31(10):1022-1024.
• [8] LJM C, JIANG L, LI W A, et al. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirusA16 in hand, f oot, and mouth disease outbreaks[J].Pediatric Infectious Disease Journal, 2011, 30(8):675.
• [9]杨波,王军,郭钜旋,等. EV71疫苗接种意愿与接种行为差异分析[J].中国公共卫生, 2017, 33(6):861-866. YANG Bo, WANG Jun, GUO Juxuan, et al. Vaccination of EV71vaccine among small children and influence of willingness of their parents to vaccination[J]. Chinese Journal of Public Health, 2017, 33(6):861-866.
• [10]朱祺,沈金花,陈文花,等.上海松江区≤6岁儿童家长对EV71疫苗接种态度及影响因素[J].中国公共卫生, 2016,32(7):885-888. ZHU Qi, SHEN Jinhua, CHEN Wenhua, et al. Attitude towards EV71 vaccination and its inf luential factors among parents of children less than six years old in Songjiang district of Shanghai[J]. Chinese Journal of Public Health, 2016, 32(7):885-888.
• [11]白云骅,李丽,张军楠,等.肠道病毒71型灭活疫苗上市后安全性主动监测[J].中国公共卫生, 2017, 33(7):1045-1047.BAI Yunhua, LI Li, ZHANG Junnan, et al. Post-marketing assessment on safety of inactivated enterovirus type 71vaccine by proactive monitoring[J]. Chinese Journal of Public Health, 2017, 33(7):1045-1047.
• [12]汪志国,汤奋扬,高君,等.肠道病毒71型灭活疫苗上市后安全性监测与评价[J].江苏预防医学, 2018, 29(6):626-629. WANG Zhiguo, TANG Fenyang, GAO Jun, et al.Post marketing surveillance and evaluation of inactivated enterovirus 71 vaccines[J]. Jiangsu Journal of Preventive Medicine, 2018, 29(6):626-629.
• [13]王雷,王四全,胡樱,等.湖北省2016-2017年肠道病毒EV71型灭活疫苗上市后安全性[J].中国疫苗和免疫, 2018,24(4):471-474. WANG Lei, WANG Siquan, HU Ying,et al. Post-marketing saf ety surveillance of inactivated enterovirus 71 vaccine in Hubei province, 2016-2017[J].Chinese Journal of Vaccines and Immunization, 2018,24(4):471-474.